 Fifty patients with mild to moderate Alzheimers disease will participate in this study. Half of the study subjects will have CERE-110 injected into the brain during a surgical procedure, while the other half will undergo a placebo surgery where no medication will be injected. All study participants will be followed for at least two years after surgery. 